title: Response to Gringeri et al.: 'Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling'.
authors.affiliation: Department of Hematology, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA.
authors.forename: A D
authors.initials: AD
authors.lastname: Shapiro
authors.affiliation: Biogen, Cambridge, MA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Li
mesh_terms: D005169:Factor VIII / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011292:Premedication; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D005169:Factor VIII